Enanta Pharmaceuticals, Inc. (ENTA) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Watertown, MA, 美国. 现任CEO为 Jay R. Luly.
ENTA 拥有 IPO日期为 2013-03-21, 131 名全职员工, 在 NASDAQ Global Select, 市值为 $339.66M.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
